DOCSLIB.ORG

Additional File 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Additional File 1 Committee for the Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock 2020 - Members' names, workplaces, conflicts of interest (COI), and roles 【policy of COI disclosure】 ・The Japanese Society of Intensive Care Medicine and the Japanese Association for Acute Medicine submitted this COI disclosure jointly, based on the same policy issued by the Japanese Association of Medical Sciences. ・Both groups used the modified submission format provided by the Japanese Association of Medical Sciences. ・In accordance with these guidelines, organizations are only required to disclose COI that relate to associated companies or for-profit organizations as financial COI. ・We asked all members to submit their financial and academic COI for the past three years （2017, 2018, and 2019）, in accordance with the current policy, shown in the last table. Panelists(Steering committee members), Organizers Financial COI Academic COI Area of GL in charge（◎group Name Workplace Position leader, ○vice group leader） A-1 A-2 A-3 A-4 A-5 A-6 A-7 A-8 A-9 B-1 B-2 B-3 C-1 C-2 Position in academic societies Cotribution to other guidelines Division of Anesthesiology, Department of Surgery ARDS clinical practice guideline committee revised version, Moritoki Egi no no no no no no no no no no no no no no no Chairman Related, Kobe University Graduate School of Medicine ARDS clinical practice guideline committee 2016 Department of Traumatology and Acute Critical Hiroshi Ogura no no no no no no no no no no no no no no no no Chairman ○WG1 Medicine, Osaka University Medical School Nara Prefecture General Medical Center Division of Kazuaki Atagi no no no no no no no no no no no no no no Critical Care Patient Safety Network President no Panelist Crtitical Care Medicine Shionogi & Co., Ltd. Department of Disaster and Emergency Medicine Shigeaki Inoue no no no no no no no no no no no no no no no Panelist Kobe University Graduate School of Medicine Department of Emergency and Disaster Medicine, International Society on Thrombosis and Haemostasis,Chairman Toshiaki Iba no no no Asahi-Kasei Pharma 2019 no Japan Blood Produxts Oranization 2018, 2019, JIMRO 2019 Ashi-Kasei Pharma 2018, 2019 no no no no no no no no Panelist Juntendo University of DIC subcomittee Japan Blood Product Organization, 2017,2018,2019 Fuso Pharmaceutical Industries、Ltd., 2017/Maruishi Department of Emergency and Intensive Care ASAHI KASEI PHARMA CORPORATION, 2017/ASAHI KASEI / Ono Pharmaceutical Co., Ltd., 2017,2018,2019 / Pharmaceutical Co., Ltd., 2017/Nipro Corporation, 2017/Ono Yasuyuki Kakihana Medicine, Kagoshima University Graduate School of no no no no PHARMA CORPORATION, 2018/ASAHI KASEI PHARMA no no no no no no no the Japanese Society of Intensive Care Medicine, Director & Council no Panelist ASAHI KASEI PHARMA CORPORATION, Pharmaceutical Co., Ltd., 2017/Ono Pharmaceutical Co., Ltd., Medical and Dental Sciences CORPORATION, 2019 2017,2018,2019 2018/FUJIFILM Toyama Chemical Co., Ltd. 2018 ARDS clinical practice guideline committee revised Department of Pediatric Critical Care, Shizuoka Tatsuya Kawasaki no no no no no no no no no no no no no no no version/Japan Resuscitation Council Resuscitation Guideline Panelist ◎WG18 Children's Hospital 2020 The Japanese Association for The Surgery of Trauma, Board member The Japanese Association for Acute Medicine, Board member Japan Advanced Trauma Evaluation and Care Guidelines, Co- Division of Emergency and Critical Care Medicine, The Japanese Society of Acute Care Surgery, Board member Shigeki Kushimoto no no no no no no no no no no no no no no chairman Panelist Tohoku University Graduate School of Medicine The Japanese Society of Acute Care Surgery, Board member Transfusion Guidelines for Patients with Massive Bleeding The Japanese Trauma Care and Research, Board member The Japanese Skin Bank Network, Board member The Japanese Society of Intensive Care Medicine, vice-chair of the Department of Emergency, Disaster, and Critical Care Yasuhiro Kuroda no no no no no no no no no no no no no no executive board, Japanese Association for Acute Medicine, Board Japan Resuscitation Council Resuscitation Guideline 2020 Panelist Medicine, Faculty of Medicine, Kagawa University Members The Japanese Society for Surgical Metabolism and Nutrition, a member Japanese Guidelines for Nutrition Support Therapy in the Adult of the executive committee and Pediatric Critically Ill Patients, director, The Japanese / The Japanese Society for Clinical Nutrition and Metabolism, a Division of Disaster and Emergency Medicine, Society of Intensive Care Medicine member of the executive committee Joji Kotani Department of Surgery Related, Kobe University no no no no no no no no no no no no no no / Japanese Guidelines for Nutrition Support Therapy in the Panelist / Japan Society for Critical Care Medicine, a member of the Graduate School of Medicine Cancer Patients, director, The Japanese Society for Clinical executive committee Nutrition and Metabolism / International Association for Surgical Metabolism and Nutrition, a member of the executive committee The Japanese Society of Intensive Care Medicine, Vice chaiman of the Department of Emergency and Critical Care Medicine, executive board; The Japanese Society of Chemotherapy, Manager of 有(MSD,2018, 2019; Phyzer,2017, 2019D; ainippon- ARDS clinical practice guideline committee revised version; Nobuaki Shime Graduate School of Biomedical & Health Sciences, no no no no no Phyzer,2017, 2018; Asahi-kasei Pharma,2017, 2018) no no no no no no no the executive board; The Japanese Society of Respiratory Care Panelist ◎WG4, ○WG9, ○WG18 Sumiutomo,2017) Japanese Guidelines for Invasive Fungal Infections Hiroshima University Medicine, Vice chaiman of the executive board; The Japanese Society of Pediatric Intensive and Critical Care Medicine, Executive board Department of Anesthesiology and Intensive Care MSD Co, Ltd 2019, Ono Pharmaceutical Co., Ltd Takumi Taniguchi no no no no no Ono Pharmaceutical Co., Ltd 2019 no no no no no no no The Japanese Society of Intensive Care Medicine, director no Panelist Medicine, Kanazawa University 2017, 2018, Pfizer Co, Ltd 2017 Acute & General Medicine, Yamaguchi Graduate Ryosuke Tsuruta no no no Pfizer Japan Inc.(2018) no no ASAHIKASEI PHARMA Co, 2017-2019 no no no no no no no no no Panelist School of Medicine Department of Acute Medicine, The University of Kent Doi no no no no no no no no no no no no no no no Surviving Sepsis Campaign Guideline Adult 2020 Panelist Tokyo Matsuyuki Doi Intensive Care Unit, Hamamatsu University Hospital no no no no no Maruishi Parmaceutial Co.,Ltd，2017 Asahi Kasei Pharma Corporation，2017，2018，2019 no no no no no no no Japan Society of Technology in Anesthesia, Director no Panelist Smart119 Japan Society for Blood Purification in Critical Care, executive board; Department of Emergency and Critical Care Medicine, Taka-aki Nakada no Inc., no no no no no no no no no no no no Japanese Association for Acute Medicine Kanto reigion, executive no Panelist Chiba University Graduate School of Medicine 2018.2019 board Department of Emergency and Critical Care Medicine, Masaki Nakane no no no no no no no no no no no no no no no Japanese Guidelines for Tracheal Suctioning 2013, Director Panelist Yamagata University Hospital Center for General Medicine Education, Keio University Seitaro Fujishima no no no no no no no no no no no no no no no no Panelist School of Medicine Department of infectious DIseases, Kameda Medical Naoto Hosokawa no no no no no no no no no no no no no no Japanese Society for Clinical Microbiology, director no Panelist Center The Japanese Society of Intensive Care Medicine, executive Department of Intensive Care Medicine, School of MSD, K.K. / Japan Blood Products Yoshiki Masuda no no no no JIMRO / Ono Pharmaceutical Co. Ltd. no no no no no no no no director/The Japan Shock Society executive director/The Japan no Panelist Medicine, Sapporo Medical University Organization/Asahi Kasei Pharma Corporation Society for Blood Purification in Critical Care, executive director. Department of Advancing Acute Medicine, Nagoya City Asako Matsushima no no no no no no no no no no no no no no no The Japanese Guidelines for Burn Injuries Panelist University, Graduate School of Medical Sciences General Incorporated Association Japan Blood Product Organization, 2017 / Ono Pharmaceutical the Japanese Society of Intensive Care Medoicone, Director & Council; Department of Emergency & Critical Care Medicine, Naoyuki Matsuda no no no Co., Ltd., 2017 / Japan Blood Product Organization, no no Kaketsuken Co., Ltd. no no no no no no no the Japanese Society of Cardiovascular Anesthesiologists, Director & no Panelist Nagoya University Graduate School of Medicine 2018 / Ono Pharmaceutical Co., Ltd., 2018 / Ono Council Pharmaceutical Co., Ltd. Department of Anesthesiology and Critical Care ARDS clinical practice guideline committee revised version, Tomoaki Yatabe no no no no no no no no no no no no no no no Panelist Medicine, Fujita Health University Japan Resuscitation Council Resuscitation Guideline 2020 Clinical practice guideline committee of the Japanese society for clinical nutrition and metabolism/ Clinical practice guideline Department of Emergency Medicine, Osaka Medical Kazuma Yamakawa no no no no no no no no no no no no no no no committee of the Japanese society on thrombosis and Panelist College hemostasis/ Resuscitation Council Resuscitation Guideline 2020/ SSCG2016（Surviving Sepsis Campaign: International Guidelines The Japanese Society of Intensive Care Medicine,
Load more

Recommended publications
  • Nilotinib in Patients with Chronic Myeloid Leukemia: STAT2 Trial in Japan
    Haematologica HAEMATOL/2018/194894 Version 3 Haematologica HAEMATOL/2018/194894 Version 3 Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan Naoto Takahashi, Kaichi Nishiwaki, Chiaki Nakaseko, Nobuyuki Aotsuka, Koji Sano, Chikako Ohwada, Jun Kuroki, Hideo Kimura, Michihide Tokuhira, Kinuko Mitani, Kazuhisa Fujikawa, Osamu Iwase, Kohshi Ohishi, Fumihiko Kimura, Tetsuya Fukuda, Sakae Tanosaki, Saori Takahashi, Yoshihiro Kameoka, Hiroyoshi Nishikawa, and Hisashi Wakita Disclosures: 1. This study was supported by research funding from Novartis Pharmaceuticals to N.T. 2. N.T reports grants from Novartis Pharmaceuticals, during the conduct of the study; grants and personal fees from Novartis Pharmaceuticals, grants and personal fees from Otsuka, grants and personal fees from Pfizer, personal fees from Bristol-Myers Squibb, outside the submitted work; K.N reports grants from Zenyaku Kogyo Company, Limited, grants from Chugai Pharmaceutical, grants from Novartis Pharma K.K., grants from Kyowa Hakko Kirin Co, Ltd, grants from Nippon Shinyaku Co, Ltd, outside the submitted work; C.N reports personal fees from Novartis, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Pfizer, grants and personal fees from Takeda pharmaceuticals, grants and personal fees from Kyowa Hakko Kirin, grants and personal fees from Otsuka Pharmaceutical, grants and personal fees from Ono Pharmaceutical, grants and personal fees from Chugai Pharmaceutical, grants and personal fees from Asahi Kasei Pharma, grants and personal fees from Shionogi, personal fees from Shire, personal fees from Jannsen, personal fees from Celgene, outside the submitted work; M.T. reports personal fees from Bristol-Myers Squib, personal fees from Pfizer, outside the submitted work; K.M reports grants from Kyowa Hakko Kirin Co.
    [Show full text]
  • Factset-Top Ten-0521.Xlsm
    Pax International Sustainable Economy Fund USD 7/31/2021 Port. Ending Market Value Portfolio Weight ASML Holding NV 34,391,879.94 4.3 Roche Holding Ltd 28,162,840.25 3.5 Novo Nordisk A/S Class B 17,719,993.74 2.2 SAP SE 17,154,858.23 2.1 AstraZeneca PLC 15,759,939.73 2.0 Unilever PLC 13,234,315.16 1.7 Commonwealth Bank of Australia 13,046,820.57 1.6 L'Oreal SA 10,415,009.32 1.3 Schneider Electric SE 10,269,506.68 1.3 GlaxoSmithKline plc 9,942,271.59 1.2 Allianz SE 9,890,811.85 1.2 Hong Kong Exchanges & Clearing Ltd. 9,477,680.83 1.2 Lonza Group AG 9,369,993.95 1.2 RELX PLC 9,269,729.12 1.2 BNP Paribas SA Class A 8,824,299.39 1.1 Takeda Pharmaceutical Co. Ltd. 8,557,780.88 1.1 Air Liquide SA 8,445,618.28 1.1 KDDI Corporation 7,560,223.63 0.9 Recruit Holdings Co., Ltd. 7,424,282.72 0.9 HOYA CORPORATION 7,295,471.27 0.9 ABB Ltd. 7,293,350.84 0.9 BASF SE 7,257,816.71 0.9 Tokyo Electron Ltd. 7,049,583.59 0.9 Munich Reinsurance Company 7,019,776.96 0.9 ASSA ABLOY AB Class B 6,982,707.69 0.9 Vestas Wind Systems A/S 6,965,518.08 0.9 Merck KGaA 6,868,081.50 0.9 Iberdrola SA 6,581,084.07 0.8 Compagnie Generale des Etablissements Michelin SCA 6,555,056.14 0.8 Straumann Holding AG 6,480,282.66 0.8 Atlas Copco AB Class B 6,194,910.19 0.8 Deutsche Boerse AG 6,186,305.10 0.8 UPM-Kymmene Oyj 5,956,283.07 0.7 Deutsche Post AG 5,851,177.11 0.7 Enel SpA 5,808,234.13 0.7 AXA SA 5,790,969.55 0.7 Nintendo Co., Ltd.
    [Show full text]
  • Research and Development in Breast Ultrasound E
    E. Ueno, T. Shiina, M. Kubota, K. Sawai (Eds.) Research and Development in Breast Ultrasound E. Ueno, T. Shiina M. Kubota, K. Sawai (Eds.) Research and Development in Breast Ultrasound With 150 Figures, Including 37 in Color 1 3 Ei Ueno, M.D., Ph.D. Associate Professor, Department of Breast-Thyroid-Endocrine Surgery Institute of Clinical Medicine, University of Tsukuba 1-1-1 Tennodai, Tsukuba, Ibaraki 304-8573, Japan Tsuyoshi Shiina, Ph.D. Professor, Institute of Information Sciences and Electronics, University of Tsukuba 1-1-1 Tennodai, Tsukuba, Ibaraki 304-8573, Japan Mitsuhiro Kubota, M.D. Director of Yamachika Memorial Hospital 3-19-14 Koyawata, Odawara, Kanagawa 256-0815, Japan Kiyoshi Sawai, M.D. Associate Professor, Department of Endocrine & Breast Surgery Kyoto Prefectural University of Medicine 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-0841, Japan Cover Illustration: Madoka Momota Library of Congress Control Number: 2004116202 ISBN 4-431-40277-2 Springer-Verlag Tokyo Berlin Heidelberg New York This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broad- casting, reproduction on microfilms or in other ways, and storage in data banks. The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. Product liability: The publisher can give no guarantee for information about drug dosage and appli- cation thereof contained in this book.
    [Show full text]
  • Compromises in Orchestra Pit Design: a Ten-Year Trench War in the Royal Theatre, Copenhagen
    Downloaded from orbit.dtu.dk on: Sep 30, 2021 Compromises in orchestra pit design: A ten-year trench war in The Royal Theatre, Copenhagen Gade, Anders Christian; Mortensen, Bo Published in: Acoustical Society of America. Journal Link to article, DOI: 10.1121/1.422278 Publication date: 1998 Document Version Publisher's PDF, also known as Version of record Link back to DTU Orbit Citation (APA): Gade, A. C., & Mortensen, B. (1998). Compromises in orchestra pit design: A ten-year trench war in The Royal Theatre, Copenhagen. Acoustical Society of America. Journal, 103(5), 2786-2786. https://doi.org/10.1121/1.422278 General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. Users may download and print one copy of any publication from the public portal for the purpose of private study or research. You may not further distribute the material or use it for any profit-making activity or commercial gain You may freely distribute the URL identifying the publication in the public portal If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. FRIDAY MORNING, 26 JUNE 1998 GRAND BALLROOMA&B~S!, 8:00 TO 9:00 A.M. Session 5aPLa Plenary Lecture Andrea Prosperetti, Chair Mechanical Engineering, Johns Hopkins University, 122 Latrobe Hall, 3400 North Charles Street, Baltimore, Maryland 21218 Chair’s Introduction—8:00 Invited Paper 8:05 5aPLa1.
    [Show full text]
  • Portfolio of Investments
    PORTFOLIO OF INVESTMENTS CTIVP® – Lazard International Equity Advantage Fund, September 30, 2020 (Unaudited) (Percentages represent value of investments compared to net assets) Investments in securities Common Stocks 97.6% Common Stocks (continued) Issuer Shares Value ($) Issuer Shares Value ($) Australia 6.9% Finland 1.0% AGL Energy Ltd. 437,255 4,269,500 Metso OYJ 153,708 2,078,669 ASX Ltd. 80,181 4,687,834 UPM-Kymmene OYJ 36,364 1,106,808 BHP Group Ltd. 349,229 9,021,842 Valmet OYJ 469,080 11,570,861 Breville Group Ltd. 153,867 2,792,438 Total 14,756,338 Charter Hall Group 424,482 3,808,865 France 9.5% CSL Ltd. 21,611 4,464,114 Air Liquide SA 47,014 7,452,175 Data#3 Ltd. 392,648 1,866,463 Capgemini SE 88,945 11,411,232 Fortescue Metals Group Ltd. 2,622,808 30,812,817 Cie de Saint-Gobain(a) 595,105 24,927,266 IGO Ltd. 596,008 1,796,212 Cie Generale des Etablissements Michelin CSA 24,191 2,596,845 Ingenia Communities Group 665,283 2,191,435 Electricite de France SA 417,761 4,413,001 Kogan.com Ltd. 138,444 2,021,176 Elis SA(a) 76,713 968,415 Netwealth Group Ltd. 477,201 5,254,788 Legrand SA 22,398 1,783,985 Omni Bridgeway Ltd. 435,744 1,234,193 L’Oreal SA 119,452 38,873,153 REA Group Ltd. 23,810 1,895,961 Orange SA 298,281 3,106,763 Regis Resources Ltd.
    [Show full text]
  • JPX-Nikkei Index 400 Constituents (Applied on August 31, 2021) Published on August 6, 2021 No
    JPX-Nikkei Index 400 Constituents (applied on August 31, 2021) Published on August 6, 2021 No. of constituents : 400 (Note) The No. of constituents is subject to change due to de-listing. etc. (Note) As for the market division, "1"=1st section, "2"=2nd section, "M"=Mothers, "J"=JASDAQ. Code Market Divison Issue Code Market Divison Issue 1332 1 Nippon Suisan Kaisha,Ltd. 3048 1 BIC CAMERA INC. 1417 1 MIRAIT Holdings Corporation 3064 1 MonotaRO Co.,Ltd. 1605 1 INPEX CORPORATION 3088 1 Matsumotokiyoshi Holdings Co.,Ltd. 1719 1 HAZAMA ANDO CORPORATION 3092 1 ZOZO,Inc. 1720 1 TOKYU CONSTRUCTION CO., LTD. 3107 1 Daiwabo Holdings Co.,Ltd. 1721 1 COMSYS Holdings Corporation 3116 1 TOYOTA BOSHOKU CORPORATION 1766 1 TOKEN CORPORATION 3141 1 WELCIA HOLDINGS CO.,LTD. 1801 1 TAISEI CORPORATION 3148 1 CREATE SD HOLDINGS CO.,LTD. 1802 1 OBAYASHI CORPORATION 3167 1 TOKAI Holdings Corporation 1803 1 SHIMIZU CORPORATION 3231 1 Nomura Real Estate Holdings,Inc. 1808 1 HASEKO Corporation 3244 1 Samty Co.,Ltd. 1812 1 KAJIMA CORPORATION 3254 1 PRESSANCE CORPORATION 1820 1 Nishimatsu Construction Co.,Ltd. 3288 1 Open House Co.,Ltd. 1821 1 Sumitomo Mitsui Construction Co., Ltd. 3289 1 Tokyu Fudosan Holdings Corporation 1824 1 MAEDA CORPORATION 3291 1 Iida Group Holdings Co.,Ltd. 1860 1 TODA CORPORATION 3349 1 COSMOS Pharmaceutical Corporation 1861 1 Kumagai Gumi Co.,Ltd. 3360 1 SHIP HEALTHCARE HOLDINGS,INC. 1878 1 DAITO TRUST CONSTRUCTION CO.,LTD. 3382 1 Seven & I Holdings Co.,Ltd. 1881 1 NIPPO CORPORATION 3391 1 TSURUHA HOLDINGS INC. 1893 1 PENTA-OCEAN CONSTRUCTION CO.,LTD.
    [Show full text]
  • TOBAM Maximum Diversification All World Developed Ex North America USD
    TOBAM Maximum Diversification All World Developed ex North America USD 31/12/2019 Instrument Weight BP PLC 0.10% IDEMITSU KOSAN CO LTD 0.21% INPEX HOLDINGS INC 0.07% JX HOLDINGS INC 0.09% NESTE OIL OYJ 1.16% OMV AG 0.08% SANTOS LTD 0.02% SBM OFFSHORE NV 0.05% TGS NOPEC GEOPHYSICAL CO ASA 0.02% VOPAK 0.02% WOOD GROUP (JOHN) PLC 0.02% AIR LIQUIDE 0.23% AIR WATER INC 0.02% AKZO NOBEL 0.12% ALUMINA LTD 0.03% AMCOR PLC-CDI 0.08% AVON RESOURCES LTD 0.53% BORAL LTD 0.02% CHR HANSEN HOLDING A/S 0.08% DAICEL CHEMICAL INDUSTRIES 0.02% DOWA HOLDINGS CO LTD 0.01% EMS-CHEMIE HOLDING AG-REG 0.03% FLETCHER BUILDING LTD 0.02% FORTESCUE METALS GROUP LTD 0.60% GIVAUDAN-REG 0.16% HITACHI CHEMICAL CO LTD 0.03% HUHTAMAKI OYJ 0.03% ISRAEL CHEMICALS LTD 0.02% JAMES HARDIE INDUSTRIES-CDI 0.07% JFE HOLDINGS INC 0.02% KANSAI PAINT CO LTD 0.03% KURARAY CO LTD 0.03% MITSUBISHI MATERIALS CORP 0.02% NEWCREST MINING LTD 1.35% TOBAM Maximum Diversification All World Developed ex North America USD 31/12/2019 Instrument Weight NIPPON PAINT CO LTD 0.05% NIPPON PAPER INDUSTRIES CO L 0.04% NIPPON SHOKUBAI CO LTD 0.01% NISSAN CHEMICAL INDUSTRIES 0.04% NOF CORP 0.02% NORTHERN STAR RESOURCES LTD 0.66% NOVOZYMES A/S-B SHARES 0.07% OJI PAPER CO LTD 0.03% ORICA LTD 0.02% ORORA LTD 0.02% SARACEN MINERAL HOLDINGS LTD 0.32% SMURFIT KAPPA GROUP PLC 0.04% SYMRISE AG 0.04% TAIHEIYO CEMENT CORP 0.02% TAIYO NIPPON SANSO CORP 0.02% TEIJIN LTD 0.02% THYSSENKRUPP AG 0.04% TORAY INDUSTRIES INC 0.02% WIENERBERGER AG 0.02% ADP 0.04% AENA SA 0.09% ALFA LAVAL AB 0.04% ALL NIPPON AIRWAYS CO LTD
    [Show full text]
  • TOPIX100 Constituents (As of October 31, 2019) No. Code Issue No. Code Issue 1 1605 INPEX CORPORATION 51 7201 NISSAN MOTOR CO.,LTD
    TOPIX100 Constituents (as of October 31, 2019) No. Code Issue No. Code Issue 1 1605 INPEX CORPORATION 51 7201 NISSAN MOTOR CO.,LTD. 2 1878 DAITO TRUST CONSTRUCTION CO.,LTD. 52 7202 ISUZU MOTORS LIMITED 3 1925 DAIWA HOUSE INDUSTRY CO.,LTD. 53 7203 TOYOTA MOTOR CORPORATION 4 1928 Sekisui House,Ltd. 54 7267 HONDA MOTOR CO.,LTD. 5 2502 Asahi Group Holdings,Ltd. 55 7269 SUZUKI MOTOR CORPORATION 6 2503 Kirin Holdings Company,Limited 56 7270 SUBARU CORPORATION 7 2802 Ajinomoto Co.,Inc. 57 7733 OLYMPUS CORPORATION 8 2914 JAPAN TOBACCO INC. 58 7741 HOYA CORPORATION 9 3382 Seven & I Holdings Co.,Ltd. 59 7751 CANON INC. 10 3402 TORAY INDUSTRIES,INC. 60 7832 BANDAI NAMCO Holdings Inc. 11 3407 ASAHI KASEI CORPORATION 61 7974 Nintendo Co.,Ltd. 12 4063 Shin-Etsu Chemical Co.,Ltd. 62 8001 ITOCHU Corporation 13 4188 Mitsubishi Chemical Holdings Corporation 63 8002 Marubeni Corporation 14 4452 Kao Corporation 64 8031 MITSUI & CO.,LTD. 15 4502 Takeda Pharmaceutical Company Limited 65 8035 Tokyo Electron Limited 16 4503 Astellas Pharma Inc. 66 8053 SUMITOMO CORPORATION 17 4507 Shionogi & Co.,Ltd. 67 8058 Mitsubishi Corporation 18 4519 CHUGAI PHARMACEUTICAL CO.,LTD. 68 8113 UNICHARM CORPORATION 19 4523 Eisai Co.,Ltd. 69 8267 AEON CO.,LTD. 20 4528 ONO PHARMACEUTICAL CO.,LTD. 70 8306 Mitsubishi UFJ Financial Group,Inc. 21 4543 TERUMO CORPORATION 71 8308 Resona Holdings, Inc. 22 4568 DAIICHI SANKYO COMPANY,LIMITED 72 8309 Sumitomo Mitsui Trust Holdings,Inc. 23 4578 Otsuka Holdings Co.,Ltd. 73 8316 Sumitomo Mitsui Financial Group,Inc. 24 4661 ORIENTAL LAND CO.,LTD.
    [Show full text]
  • R&Co Risk-Based Japan Index
    Rothschild & Co Risk-Based Japan Index Indicative Index Weight Data as of June 30, 2021 on close Constituent Exchange Country Index Weight(%) McDonald's Holdings Co Japan L Japan 1.29 Idemitsu Kosan Co Ltd Japan 1.12 SoftBank Corp Japan 1.05 Nintendo Co Ltd Japan 0.86 Hitachi Metals Ltd Japan 0.83 Yakult Honsha Co Ltd Japan 0.82 Iwatani Corp Japan 0.81 ENEOS Holdings Inc Japan 0.79 FUJIFILM Holdings Corp Japan 0.78 KDDI Corp Japan 0.75 Toshiba Corp Japan 0.73 Calbee Inc Japan 0.73 Ajinomoto Co Inc Japan 0.72 Eisai Co Ltd Japan 0.72 Nissin Foods Holdings Co Ltd Japan 0.71 Morinaga Milk Industry Co Ltd Japan 0.70 Japan Tobacco Inc Japan 0.66 H.U. Group Holdings Inc Japan 0.66 JCR Pharmaceuticals Co Ltd Japan 0.64 MEIJI Holdings Co Ltd Japan 0.64 Yamazaki Baking Co Ltd Japan 0.63 Chugoku Electric Power Co Inc/ Japan 0.63 Nippon Gas Co Ltd Japan 0.63 PeptiDream Inc Japan 0.62 Chubu Electric Power Co Inc Japan 0.62 Seven & i Holdings Co Ltd Japan 0.62 FP Corp Japan 0.61 Pola Orbis Holdings Inc Japan 0.61 Lion Corp Japan 0.61 Shiseido Co Ltd Japan 0.60 Nippon Telegraph & Telephone C Japan 0.60 Nichirei Corp Japan 0.59 Japan Post Bank Co Ltd Japan 0.59 Kobayashi Pharmaceutical Co Lt Japan 0.59 Anritsu Corp Japan 0.58 Skylark Holdings Co Ltd Japan 0.58 Kyowa Kirin Co Ltd Japan 0.58 Lawson Inc Japan 0.58 Suntory Beverage & Food Ltd Japan 0.57 Kinden Corp Japan 0.57 MS&AD Insurance Group Holdings Japan 0.56 Shimano Inc Japan 0.56 Mitsubishi Corp Japan 0.56 Zensho Holdings Co Ltd Japan 0.56 Tokai Carbon Co Ltd Japan 0.56 Japan Post Holdings Co Ltd
    [Show full text]
  • Internet Disclosure Accompanying the Notice of Convocation the 117Th Ordinary General Meeting of Shareholders (Voluntary Disclosure)
    March 6, 2017 Internet Disclosure Accompanying the Notice of Convocation The 117th Ordinary General Meeting of Shareholders (Voluntary Disclosure) Voluntary Disclosure Relating to “3. Matters Concerning Shares Held by the Company” on the Business Report of the Company The 30 Largest Stock-Holdings of Publicly Listed Companies in the Amount on the Balance Sheet, Which the Company Holds for Purposes Other Than Realizing Direct Investment Gains ································································································· 1 Voluntary Disclosure Relating to “5. Matters Concerning Status of Corporate Governance and Directors, Audit & Supervisory Board Members and Corporate Officers of the Company” of the Business Report of the Company Criteria for Independence of “External Directors and Audit & Supervisory Board Members” ······························································································· 2 Criteria for “Important Concurrent Position” Assumed by Company’s Directors and Audit & Supervisory Board Members···························································· 6 Criteria for Stating the Relationship between the Company and the Organizations in Which the Company’s Directors and Audit & Supervisory Board Members Hold “Important Concurrent Positions” ················································································· 7 The 30 Largest Stock-Holdings of Publicly Listed Companies in the Amount on the Balance Sheet, Which the Company Holds for Purposes Other Than Realizing Direct Investment
    [Show full text]
  • Corporate Profile
    Corporate Profile Namiki Shoji Co., Ltd.: A trading company involved in marketing pharmaceuticals, compounds for drug discovery, intermediates, and health foods; and providing various biological evaluation services of compounds. Continues to be chosen as a strategic partner by numerous clients, including major Japanese pharmaceutical companies. Launched in 1974 as a company trading in raw materials of generic pharmaceuticals. We later started importing and marketing drug-discovery compounds (compounds for new drug development), first time in Japan. We continue to supply high-quality drug-discovery compounds and intermediates required at the cutting edge of new drug development, and we are holding a firm position with a top share in this field. With the support of our Pharmaceutical Dept., Drug Discovery Chemicals Dept., and Biological Research Dept., we constantly strive to supply products and services giving our clients 100% satisfaction. We hope, by means of these commercial activities, to play a significant role in radical new drug development, and our satisfaction lies in any contribution to human health. 1 Corporate Profile Greetings from the President "By mutually beneficial commercial activities, we grow together with our clients" Tatsuya Namiki Company President With our philosophy of "By mutually beneficial commercial activities, we grow together with our clients", at Namiki Shoji our aim is to expand our business energetically, in our role as the strategic partner of pharmaceutical companies. Since the founding of Namiki Shoji, we have constantly striven to develop radical new products and services to satisfy our clients, in a creative manner, rising to all challenges presented. Our business now has two pillars: Pharmaceuticals, and compounds for drug discovery.
    [Show full text]
  • Comprehensive List of Pharmaceuticals-Related Projects
    Pharmaceutical and R&D Facilities Facility Type Photo Client Location Completion Scope Wakayama/ Solid Dosage TAMURA PHARMACEUTICAL CO.,LTD. 2019 EPCV Japan Gunma/ Bio Bulk DAIICHI SANKYO CHEMICAL PHARMA CO., LTD. 2019 EPCV Japan Hyogo/ R&D Center KANAE CO.,LTD. 2019 EPC Japan API undisclosed Tohoku/Japan 2017 EPCV R&D Center JSR Corporation Tokyo/Japan 2017 EPCV API undisclosed Kitakanto/Japan 2017 EPCV Yamaguchi/ R&D Center TEIJIN PHARMA LIMITED 2015 EPCV Japan Medical Device Menicon Co., Ltd. Chubu/Japan 2014 EPCV Fukushima/ R&D Center SANWA KAGAKU KENKYUSHO CO., LTD. 2014 EPCV Japan Yamaguchi/ Medical Device Terumo Yamaguchi Corporation 2014 E+ES Japan TOYAMA CHEMICAL CO., LTD. Toyama/ Parenteral 2013 EPCV (Current name:FUJIFILM Toyama Chemical Co., Ltd.) Japan Astellas Pharma Inc. Aichi/ Bio Bulk 2013 EPCV (Current name:Micro Biopharm Japan Co.,Ltd.) Japan Kanagawa/ R&D Center Mitsubishi Tanabe Pharma Corporation 2011 EPC Japan Hiroshima/ R&D Center YASUHARA CHEMICAL CO., LTD. 2010 EPC Japan Fukushima/ API TOA EIYO LTD. 2009 EPCV Japan Gunma/ R&D Center SANDEN HOLDINGS CORPORATION 2008 EPC Japan Hyogo/ Packaging KANAE CO., LTD. 2008 EPCV Japan ASAHI GLASS CO., LTD. Chiba/ Bio Bulk 2008 EPCV (Current name:AGC Inc.) Japan 1 / 3 Iwate/ Aseptic API Shionogi & Co., Ltd. 2007 EPCV Japan Mie/ Solid Dosage Sumitomo Dainippon Pharma Co., Ltd. 2007 EPCV Japan Saitama/ Nutrition/Liquid Taisho Pharmaceutical Co., Ltd. 2007 EPCV Japan Kaketsuken Kumamoto/ Vaccine (The Chemo-sero-therapeutic Research Institute) 2006 EPCV Japan (Current name:KM Biologics Co., Ltd.) Niigata/ Vaccine Denka Seiken Co., Ltd. 2006 EPCV Japan Shizuoka/ Bio Bulk Yamaha Motor Co., Ltd.
    [Show full text]